Navigation Links
Quantitation of Cabergoline at Extremely Low Plasma Concentrations with ,,, a Triple Quadrupole Mass Spectrometer

Nicola Hughes,1 Antony Harvey,2 Witold Winnik,3 Jean-Jacques Dunyach,2 Maan Amad,2 Maurizio Splendore,2 and Gary Paul3

1Biovail Contract Research,Toronto,Ontario,Canada;
2Thermo Finnigan,San Jose,CA,USA;
3Thermo Finnigan,Somerset, NJ,USA

Systemic Plasma Analysis

The data presented here was acquired on a Thermo Finnigan TSQ Quantum mass spectrometer

Overview

Quantitation of low plasma concentrations of the pharmaceutical cabergoline is performed to demonstrate the sensitivity and selectivity of the TSQ Quantum mass spectrometer. Samples with analyte concentrations ranging five orders of magnitude are analyzed to demonstrate precision and accuracy over a linear dynamic range suitable for pharmacokinetic applications. Analysis of 50 fg of cabergoline on column in minimally treated plasma samples is performed to demonstrate the sensitivity, ruggedness, and practicality of the bioanalytical method in a complex matrix.

Introduction

Pharmaceuticals with potent activity achieve their desired therapeutic effects when administered at low doses. Consequently, their systemic plasma levels are extremely low and require highly sensitive techniques for detection. Cabergoline, a synthetic ergoline derivative with a powerful dopaminergic activity, is usually administered in 0.25 mg, biweekly doses, yielding plasma concentrations in the pg/mL level.[1,2]

A variety of analytical methods have been employed to quantify low levels of cabergoline in plasma; these include high performance liquid chromatography (HPLC), radioimmunassay (RIA), and liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS). Techniques utilizing HPLC alone proved to have insufficient detection limits.[3,4] RIA also does not have an adequate lower limit of quantitation (LLOQ) suitable for monitoring cabergoline when administered at low doses.[1,5] And while recent LC/MS/MS methods have shown improvement in sensitivity through the use of selected reaction monitoring (SRM), they still require large sample volumes and time-consuming sample preparation.[6,7] Consequently, these methods either lack the sensitivity, dynamic range, or practicality required for routine, high-throughput pharmacokinetic applications. To assess the feasibility of using the TSQ Quantum to address these application requirements, cabergoline was analyzed in the LC/ESI/SRM, unit-resolution mode. Significant improvement in sensitivity was demonstrated on the TSQ Quantum compared to the previous generation triple quadrupole mass spectrometer from Thermo Finnigan, the TSQ 7000.[811] Using the TSQ Quantum, low femtogram-levels of cabergoline were resolved from the complex plasma matrix. Excellent precision and accuracy were maintained over five orders of magnitude, demonstrating a linear dynamic range suitable for real-world, pharmacokinetic applications.[8,9,12]

Goals

1) Analyze low-level plasma concentrations of cabergoline in a complex matrix.

2) Demonstrate a dynamic linear response of method more suitable for pharmacokinetic applications.

3) Compare the method performance of the TSQ Quantum to that of an earlier-generation mass spectrometer.

Experimental Conditions

Chemicals and Reagents: Cabergoline (purity >99%) was chemically synthesized. Pergolide mesylate (purity >98%) was supplied by Sigma Chemical Company (St. Louis, MO, USA). HPLCgrade acetonitrile and methanol, and reagentgrade ammonium acetate were purchased from EM Sciences (Gibbstown, NJ, USA). Bovine plasma was acquired from Sigma Chemical Company.

Standard and Sample Preparation: Primary stock solutions of cabergoline and the internal standard pergolide (Figure 1) were each prepared at a concentration of 1 mg/mL in methanol and stored at 25 C. A plasma solution was prepared by precipitating bovine plasma with a 2 volume of acetonitrile. A 1 g/mL cabergoline plasma standard was prepared by spiking the precipitated bovine plasma with the cabergoline stock solution. Working plasma standards were prepared by sequentially diluting the 1 g/mL cabergoline plasma standard with the precipitated bovine plasma solution to yield final concentrations ranging from 10 pg/mL to 1 g/mL. Prior to analysis, each standard level was spiked with the pergolide stock solution to produce the fixed internal standard concentration of 200 ng/mL of pergolide. The plasma standards were then ready for direct injection into the HPLCno further sample clean up was necessary.


Figure 1. Structures of cabergoline and pergolide.



Figure 2. LC/ESI/SRM chromatogram of 50 fg on column of cabergoline (m/z 452 381) and 1 ng on column of pergolide internal standard (m/z 315208) in plasma under unit resolution conditions.



Figure 3. LC/ESI/SRM chromatograms of drug-free plasma under unit resolution conditions.

Sample Analysis: HPLC analysis was performed on the Thermo Finnigan Surveyor LC System. The chromatographic separation was performed using isocratic conditions on an XTerra MS C18, 5 m, 2.1 150 mm column (Waters Corporation, Milford, MA, USA) with a mobile phase of acetonitrile/ ammonium acetate (60:40, v/v). The LC flow rate was 0.3 mL/min and the injection volume was 5 L.

Detection was performed on the TSQ Quantum mass spectrometer equipped with the ESI source (Thermo Finnigan, San Jose, CA, USA).

The general MS conditions were as follows:
Source: ESI
Ion Polarity: Positive
Spray Voltage: 4600 V
Sheath / Auxiliary Gas: Nitrogen
Sheath Gas Pressure: 75 arb units
Auxiliary Gas Pressure: 25 arb units
Ion Transfer Capillary Temperature: 360 C
Scan Type: SRM
Collision Gas: Argon
Collision Gas Pressure: 1.5 mTorr


Figure 4. Calibration curve for cabergoline in plasma under unit resolution conditions covering 1 x 105 orders of linear dynamic range (50 fg to 5 ng on column), R > 0.999 using 1/x weighted regression.

The cabergoline SRM conditions were as follows:

Parent Mass: 452 m/z
Product Mass: 381 m/z
Scan Width: 0.7 u
Scan Time: 0.50 s
Collision Energy: 19 eV
Q1 Peak Width: 0.70 u FWHM
Q3 Peak Width: 0.70 u FWHM The pergolide SRM conditions were as follows:

Parent Mass: 315 m/z
Product Mass: 208 m/z
Scan Width: 0.7 u
Scan Time: 0.50 s
Collision Energy: 27 eV
Q1 Peak Width: 0.70 u FWHM
Q3 Peak Width: 0.70 u FWHM


Table 1. Precision and accuracy in the LC/ESI/SRM analysis of cabergoline in plasma under unit resolution conditions. n >=5 samples at each calibration level.

Discussion

The quantitative LC/ESI/SRM results for cabergoline on the TSQ Quantum at unit resolution are summarized in Figures 24 and in Table 1. The LLOQ observed for cabergoline was 50 fg on column (5 L injection of 10 pg/mL) which gave a S/N ratio of 23 (Figure 2). Bioanalytical methods for the pharmacokinetic analysis of cabergoline ideally require detection limits of 12 pg/mL in plasma. This is easily accomplished on the TSQ Quantum since an LLOQ of 50 fg on column represents only 5% (50 L) of a 1 mL plasma sample containing 1 pg of cabergoline. By extrapolation, it is clear that extremely sensitive limits of detection (down to the low pg/mL level for cabergoline) can be achieved with small plasma sample volumes.

A significant advantage of using smaller plasma volumes is that it lends itself to improved pharmacokinetic analyses, as replicate and other large samples-per-subject study designs would not be limited by the plasma volume requirements of the assay. The ability to easily attain such low detection limits on the TSQ Quantum with complex plasma samples also negates the need to develop highly selective sample enrichment procedures to minimize matrix interferences and to maximize the amount of analyte injected on the column.[67] The method used here is in marked contrast to a previous method for cabergoline developed on the older generation TSQ 7000 triple quadrupole mass spectrometer, which reported an LLOQ value of 1.86 pg/mL (S/N ratio of 1813.1). However, this LLOQ actually represents ~900 fg of cabergoline on column[6] rather than the 50 fg on column reported here. Furthermore, in order to acquire an accurate, reproducible LLOQ for cabergoline on the TSQ 7000, the assay required use of a 1-mL plasma sample, a complex extraction procedure including a five-fold enrichment of the analyte concentration, and a large injection volume (150 L) representing 75% of the extracted sample.[6] In contrast, using the TSQ Quantum, superior cabergoline sensitivity was achieved with minimally-treated samples and a much smaller injection volume (5 L). Thus, the detection limit for cabergoline on the TSQ Quantum is almost 20 times lower than that attained on the TSQ 7000.[6,8,11] The calibration curve for cabergoline obtained on the TSQ Quantum shows a linear dynamic range covering 5 orders of magnitude (1 x 105) with a correlation coefficient of R > 0.999 using a weighting factor of 1/x (Figure 4). Intra-assay accuracy and precision was evaluated for n >= 5 samples at each calibration level. The accuracy and precision numbers obtained over this extended linear dynamic range are shown in Table 1. The LLOQ (50 fg on column) had an accuracy (%RE) and precision (%CV) of 13.6% and 9.3% respectively. The %RE and %CV for all the other calibration levels (0.5 pg to 5000 pg on column) ranged from -7.5% to 1.6% and 0.5 to 8.4%, respectively. The linear dynamic range for the TSQ Quantum is considerably broader than that achievable on the TSQ 7000 (which was less than 2 orders of magnitude for this assay).[6,7] The significance of this extended linear dynamic range is that a single method can now be developed for cabergoline for application in both low and high dose pharmacokinetic analyses.

It is typical for the response of older generation mass spectrometers to be nonlinear and/or for detector saturation to occur for linear dynamic ranges as low as 3 orders of magnitude. This is particularly problematic for assays where drugs and their metabolites are present in vastly different concentrations and for the analysis of drug combination products. Typically, method development is biased towards optimizing the detection limit for the lower concentration analyte, sacrificing detector saturation of the higher concentration analytes. Since linear range of the high concentration analyte is compromised, sample dilution and subsequent analysis becomes unavoidable; this contributes considerably to overall sample analysis time and, thus, does not lend itself to highthroughput applications. Hence, the extended linear dynamic range of the TSQ Quantum is extremely beneficial in these situations.

Conclusions

The TSQ Quantum operated at unit resolution shows tremendous utility in the development of highly sensitive detection methods for ergoline derivatives such as cabergoline. Sensitivity on the TSQ Quantum is ~20 times better than that reported on the TSQ 7000 while only requiring a fraction of the sample previously used. Furthermore, analysis of low plasma concentrations of cabergoline was performed in a complex, minimally treated plasma matrix. The broad dynamic range of the TSQ Quantum, coupled with the excellent precision and accuracy in unit resolution, is of particular importance for applications where detector saturation is typically encountered. The broad dynamic range, therefore, allows for easy development of methods suitable for the analysis of drugs administered at any given dose (low and high), for drugs and their metabolites, and for drug combination products. For these reasons, the TSQ Quantum should find widespread use in the development of sensitive, simple, fast, accurate, and rugged methods for many pharmacokinetic applications.

References

1. Andreotti AC, Pianezzola E, Persiani S, Pacciarini MA, Strolin Benedetti M, Pontiroli, AE. J. Clin. Endocrinol. Metab. 1995; 80: 841.
2. Rinne UK, Bracco F, Chouuza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R, the Pharmacokinetic S009 Collaborative Study Group. Neurology, 1997; 48: 363.
3. Pianezzola E, Bellotti V, La Croix R, Benedetti MS. J. Chromatogr. B. 1992; 574: 170.
4. Kerr KM, Smith RV, Davis PJ. J. Chromatog. 1981; 219: 317.
5. Persiani S, Pianezzola E, Britin F, Fonte G, Strolin Benedetti M. J. Immunoassay. 1992; 13: 457.
6. Allevi C, Dostert P. Rapid Commun. Mass Spectrom. 1998; 12: 33.
7. Couture J, Gonthier R, Valle F. AAPSPharmSci, 2001, 3.
8. Xu X, Wainhaus S, Tucker G, Veals J, Korfmacher W. 49th ASMS Conf Mass Spectrometry and Allied Topics, Chicago, IL, 2001.
9. Xu, X, Tucker, G, Wainhaus S, Veals J, Korfmacher W. 50th ASMS Conf Mass Spectrometry and Allied Topics, Orlando, FL, 2002.
10. Folk B, Burton R, P, Price P, Newton J. 49th ASMS Conf Mass Spectrometry and Allied Topics, Chicago, IL, 2001.
11. Ospina M, Woolfitt AR, Wu WW, Vesper H, Barr JR, Myers G. 50th ASMS Conf Mass Spectrometry and Allied Topics, Orlando, FL, 2002.
12. Yang N, Wu J, Chen, Rudewicz PJ, Amad M, Campbell C, Winnik WM, Schweingruber H, Mylchreest I. 49th ASMS Conf Mass Spectrometry and Allied Topics, Chicago IL, 2001.





'"/>

Source:


Page: All 1 2 3 4 5 6 7 8

Related biology technology :

1. Bioanalytical Method Intraday Validation for the Quantitation of Paroxetine in Bovine Plasma using the TSQ Quantum Mass Spectrometer
2. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
3. Comparison of Different Methods of mRNA Quantitation
4. Quantitation of DNA for Automated Sequencing Using the VersaFluor Fluorometer
5. Quantitation of RNA for Hybridization Blots Using the VersaFluor Fluorometer
6. Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A
7. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
8. Benchmark Plus Microplate Reader: Quantitation of Protein Concentration Using Two Different Colorimetric Assay Kits, Rev A
9. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
10. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
11. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
Post Your Comments:
(Date:3/30/2015)... 2015  Heidrick & Struggles (Nasdaq: HSII ), the ... and culture shaping worldwide, today  announced that ... its global Healthcare and Life Sciences practice. As ... will lead a team of more than 80 partners, principals ... and Asia serving clients in the ...
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... Drug Administration (CFDA) has approved the Company,s application to ... clear cell carcinoma (OCCC) patients for its proprietary drug ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015  FUJIFILM ... ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: Robert ... leading developer and manufacturer of fully functioning human cells ... the two companies have entered into a definitive agreement ... offer to be followed by a second step merger. ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8
... national retail drug ... chain, ... of patented pain relief products, today announced that Walgreens,the nation,s largest drugstore ... all of its 6,237 stores.,Its introduction onto Walgreens, shelves across the United ...
... Policy, SAN CARLOS, Calif., April 8, ... Services (CMS) have approved at-home sleep testing,for ... mandated that,suspected sleep apnea sufferers undergo facility-based ... pressure (CPAP) treatment for,Medicare patients who are ...
... the American College of Cardiology 57th Annual ... Scientific ... VRML ), a molecular diagnostics company, presented data from a,study ... the diagnosis of peripheral artery disease,(PAD). The research suggests that such ...
Cached Biology Technology:ALCiS(R) Daily Relief Now Available at Walgreens 2Medicare Approves in Home Sleep Apnea Testing 2Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease 2Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease 3
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... baby boomers and subsequent generations will be looking to the ... longer, healthier and more active lives than previous generations, according ... 12 meeting. There are 78 million baby boomers, defined ... 1, 1946, to Dec. 31, 1964 in the United States. ...
... Eating foods at breakfast that have a low glycemic index ... morning and after the next meal of the day, researchers ... These breakfast foods also can increase feelings of satiety ... throughout the day, acdcording to presentations Wednesday by Kantha Shelke, ...
... series at the University of Houston (UH) will give Houstonians an ... and medicine. The first of five lectures will be held from ... of Houston. The theme of the evening series will ... obesity, heart disease and cancer. Sponsored by the College of Natural ...
Cached Biology News:Glycemic index foods at breakfast can control blood sugar throughout the day 2New UH lecture series examines impact of science on health 2
... LiCl precipitation offers major advantages over other RNA ... DNA, protein or carbohydrates. It is the method ... cDNA synthesis from RNA preparations. Note, LiCl precipitation ... RNA isolations. If the RNA is to be ...
...
...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
Biology Products: